Inovio Pharmaceuticals (Nasdaq: INO) prices $20.0 million stock and warrant deal

Rhea-AI Filing Summary

Inovio Pharmaceuticals, Inc. entered into an underwriting agreement with Piper Sandler for a public offering of 21,052,632 shares of common stock and accompanying warrants to purchase up to 42,105,264 shares of common stock, at a combined public offering price of $0.95 per share of common stock and accompanying warrant.

Each warrant is immediately exercisable for two shares at an exercise price of $1.10 per share (or $1.099 per pre-funded warrant) and will expire five years from issuance, subject to beneficial ownership limits of 4.99%, 9.99% or 19.99% as elected by the holder. The underwriter has a 30‑day option to purchase up to 3,157,894 additional shares and/or warrants to purchase up to 6,315,788 shares and has exercised this option with respect to the additional warrants.

Gross proceeds are expected to be approximately $20.0 million before underwriting discounts and commissions and offering expenses, excluding any exercise of the underwriter’s option to purchase additional securities and assuming no exercise of the accompanying warrants. Net proceeds to Inovio are expected to be about $18.3 million after such costs, including the underwriter’s purchase of additional warrants and assuming no exercise of its option to purchase additional shares, with closing expected on or about July 31, 2026, subject to customary conditions.

Filing Explained

The underwritten offering could dilute existing holders through 21,052,632 new shares and warrants for additional shares, but closing remains pending.

As a Form 8-K, this filing reports that INOVIO has entered an underwriting agreement for a public offering; the closing remained expected on or about July 31, 2026, so the new shares and warrants were not yet reported as issued. If completed, the offering would add 21,052,632 shares of common stock, creating dilution for existing holders, while the warrants could add further shares if exercised.

The accompanying warrants cover 42,105,264 shares and are immediately exercisable for five years, while the underwriter exercised its option for warrants covering another 6,315,788 shares. The option exercise expands the disclosed warrant-linked share capacity, but it does not itself issue those shares.

Exercise is subject to holder ownership limits of 4.99%, 9.99%, or 19.99%, as elected by the holder. Where common-stock exercise is blocked by that limit, the holder may instead receive pre-funded warrants with a $0.001 exercise price; those instruments convert to shares when exercised.

In a defined fundamental transaction, the warrants can provide securities, cash, or other property, and the holder may instead elect a fair-value purchase of the warrant under the stated Black-Scholes method. The specific resolution point is the closing, which remains subject to customary conditions; the filing does not report completion or receipt of the expected $18.3 million net proceeds.

8-K Event Classification

3 items: 1.01, 8.01, 9.01

3 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Shares offered: 21,052,632 shares of common stock Warrant coverage: 42,105,264 shares of common stock Unit offering price: $0.95 per share of common stock and accompanying warrant +5 more

8 metrics

Shares offered 21,052,632 shares of common stock Number of common shares in the underwritten public offering

Warrant coverage 42,105,264 shares of common stock Maximum number of shares underlying accompanying warrants

Unit offering price $0.95 per share of common stock and accompanying warrant Combined public offering price for each share and accompanying warrant

Warrant exercise price $1.10 per share of Common Stock Exercise price per share under the warrants in the offering

Underwriter option shares 3,157,894 additional shares Maximum additional common shares subject to 30‑day underwriter option

Underwriter option warrants 6,315,788 additional shares of Common Stock Maximum additional warrant coverage under 30‑day underwriter option

Gross proceeds $20.0 million Expected gross proceeds before fees, excluding any option or warrant exercises

Net proceeds $18.3 million Expected net proceeds after underwriting discounts and estimated expenses, including additional warrants

Key Terms

underwriting agreement, underwritten public offering, pre-funded warrants, beneficially owned, +2 more

6 terms

underwriting agreement financial

"entered into an underwriting agreement with Piper Sandler & Co., as underwriter"

An underwriting agreement is a contract where a company selling new stocks or bonds hires financial firms to buy those securities and resell them to investors. It matters because the agreement sets the offering price, number of securities, fees and which party bears the risk if sales fall short—think of it as a promise that the sale will happen and a roadmap investors can use to understand how the new securities reach the market.

underwritten public offering financial

"to offer and sell shares of its common stock and accompanying warrants in an underwritten public offering"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

pre-funded warrants financial

"warrants to purchase up to 42,105,264 shares of its Common Stock (or pre-funded warrants in lieu thereof)"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

beneficially owned regulatory

"would cause the aggregate number of shares of Common Stock beneficially owned by such holder"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

fundamental transaction financial

"in certain circumstances, upon a fundamental transaction (as described in the Warrants)"

shelf registration statement regulatory

"A shelf registration statement relating to the shares of common stock and accompanying warrants"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 07/31/2026 - 07:23 AM Accepted by SEC EDGAR 07/31/2026 - 07:23 AM Learn about SEC filing dates

FAQ

What securities is Inovio (INO) offering in this new deal?

Inovio is offering 21,052,632 shares of common stock with accompanying warrants to purchase up to 42,105,264 shares of common stock. Each unit is priced at $0.95 per share of common stock and accompanying warrant to purchase two shares.

How much capital does Inovio (INO) expect to raise from this offering?

The offering is expected to generate gross proceeds of approximately $20.0 million before fees. Net proceeds to Inovio are expected to be about $18.3 million after underwriting discounts, commissions and estimated expenses, including the underwriter’s purchase of additional warrants.

What are the key terms of the warrants issued by Inovio (INO)?

Each warrant is immediately exercisable for two shares of common stock at an exercise price of $1.10 per share (or $1.099 per pre-funded warrant) and will expire five years from issuance, subject to specified beneficial ownership limitations.

Does the Inovio (INO) underwriter have an option to buy additional securities?

Yes. Piper Sandler has a 30‑day option to purchase up to 3,157,894 additional shares and/or warrants to purchase up to 6,315,788 shares. The underwriter has already exercised this option with respect to the additional warrants only.

What ownership limits apply to the new Inovio (INO) warrants?

Warrant holders cannot exercise if it would push their beneficial ownership above 4.99%, 9.99% or 19.99% of outstanding common stock, depending on their prior election, with the ability to adjust up to but not exceeding 19.99% on notice.

Under what registration is Inovio (INO) conducting this offering?

The securities are being issued under Inovio’s shelf registration statement on Form S-3 (File No. 333-297233), which was declared effective by the SEC on July 10, 2026, and are described in an accompanying prospectus supplement.

false 0001055726 0001055726 2026-07-29 2026-07-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 29, 2026

Inovio Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-14888		33-0969592
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

660 W. Germantown Pike, Suite 110

Plymouth Meeting, PA 19462

(Address of principal executive offices, including zip code)

(267) 440-4200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		INO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On July 29, 2026, Inovio Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co., as underwriter (the “Underwriter”), relating to the issuance and sale by the Company in a public offering of (i) 21,052,632 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) accompanying warrants (the “Warrants”) to purchase up to 42,105,264 shares of its Common Stock (or pre-funded warrants in lieu thereof (the “Pre-Funded Warrants”)) at an exercise price of $1.10 per share of Common Stock (or 1.099 per Pre-Funded Warrant to purchase a share of common stock), at a combined public offering price of $0.95 per share of Common Stock and accompanying Warrant (the “Offering”).

The Company also granted the Underwriter an option for a period of 30 days to purchase up to 3,157,894 additional shares of Common Stock and/or warrants to purchase up to 6,315,788 additional shares of Common Stock (or pre-funded warrants in lieu thereof) at the public offering price, less the underwriting discounts and commissions. On July 29, 2026, the Underwriter exercised such option with respect to the warrants to purchase up to 6,315,788 additional shares of Common Stock (or pre-funded warrants in lieu thereof).

The net proceeds to the Company from the Offering, including the exercise of the Underwriter’s option to purchase additional warrants, are expected to be approximately $18.3 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, and assuming no exercise of the Underwriter’s option to purchase additional shares. All of the Shares and the Warrants are being sold by the Company. The Offering is expected to close on or about July 31, 2026, subject to the satisfaction of customary closing conditions.

The Offering was made pursuant to the Company’s registration statement on Form S-3 (File No. 333-297233), which was declared effective by the Securities and Exchange Commission (the “SEC”) on July 10, 2026, as supplemented by a prospectus supplement filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”).

Each Warrant entitles the holder thereof to purchase two shares of Common Stock (or to purchase a pre-funded warrant in lieu thereof) with an exercise price of $1.10 per share (or $1.099 per Pre-Funded Warrant to purchase one share of Common Stock), will be immediately exercisable and will expire five (5) years from the date of issuance.

A holder of the Warrants will not be entitled to exercise any portion of such Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates, any other persons acting as a group together with the holder and any other persons whose beneficial ownership of Common Stock would be aggregated with the holder for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended) to exceed 4.99%, 9.99% or 19.99% (or such other percentage that was elected by the holder prior to the issuance of the Warrant) of the number of shares of Common Stock outstanding immediately after giving effect to the exercise. If a holder holds less than 20% of the number of shares of Common Stock outstanding prior to giving effect to the issuance of shares issuable upon exercise, then, upon at least 61 days’ prior notice from such holder, subject to the terms of the Warrants, such holder may increase or decrease such percentage to any other percentage not in excess of 19.99%. If the holder is not permitted to exercise a Warrant for common stock due to the foregoing limitation, then the holder may exercise such Warrant for an equivalent number of Pre-Funded Warrants, each with an exercise price per Pre-Funded Warrant of $0.001.

In addition, in certain circumstances, upon a fundamental transaction (as described in the Warrants), a holder of Warrants will be entitled to receive, upon exercise of the Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Warrants immediately prior to such fundamental transaction or number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation. In lieu of receiving such Common Stock in the fundamental transaction, the Warrant holder may elect to have the Company or the successor entity purchase the holder’s Warrant for its fair market value measured by the Black-Scholes method.

The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties.

The foregoing descriptions of the terms of the Underwriting Agreement and Warrants are each qualified in their entirety by reference to the Underwriting Agreement, form of Pre-Funded Warrant and form of Warrant, respectively, which are attached as Exhibit 1.1, Exhibit 4.1 and Exhibit 4.2 hereto, respectively, and incorporated by reference herein.

A copy of the legal opinion of Cooley LLP relating to the validity of the issuance and sale of the securities in the Offering is attached as Exhibit 5.1 hereto.

Item 8.01 Other Events

On July 29, 2026, the Company issued press releases announcing the launch and pricing of the Offering, respectively, copies of which are filed as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the Offering, such as the expected net proceeds and anticipated closing date. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding the Company’s business are described in detail in its SEC filings, including in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which is available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that the Company makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligation to update these statements except as may be required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Exhibit Description
1.1		Underwriting Agreement, dated July 29, 2026, by and between Inovio Pharmaceuticals, Inc. and Piper Sandler & Co.
4.1		Form of Pre-Funded Warrant.
4.2		Form of Warrant.
5.1		Opinion of Cooley LLP.
23.1		Consent of Cooley LLP (included in Exhibit 5.1).
99.1		Press Release.
99.2		Press Release.
104		Cover Page Interactive Data File (formatted as inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						INOVIO PHARMACEUTICALS, INC.
Date: July 31, 2026						/s/ Peter Kies
						Peter Kies
						Chief Financial Officer

Exhibit 99.1

INOVIO Announces Proposed Public Offering

PLYMOUTH MEETING, PA – July 29, 2026 /PRNewswire/ – INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof), in an underwritten public offering. INOVIO intends to grant the underwriter a 30-day option to purchase additional shares of its common stock and/or accompanying warrants in an amount up to 15% of the shares of its common stock and/or accompanying warrants offered in the public offering under the same terms and conditions. All of the securities in the proposed offering will be sold by INOVIO. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Piper Sandler is acting as sole manager for the offering.

A shelf registration statement relating to the shares of common stock and accompanying warrants offered in the offering described above was filed with the Securities and Exchange Commission (“SEC”) on July 2, 2026 and declared effective by the SEC on July 10, 2026. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting: Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by e-mail at prospectus@psc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO’s technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools.

Forward-Looking Statements

This release contains or may imply “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding INOVIO’s anticipated public offering, including the completion of the public offering on the anticipated terms, if at all, and INOVIO’s plans to grant the underwriter a 30-day option to purchase additional shares and/or warrants. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in INOVIO’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and in other filings that INOVIO makes with the SEC from time to time. There can be no assurance that any of the forward-looking information provided herein will be proven accurate. These forward-looking statements speak only as of the date hereof and INOVIO undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

Contacts

Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com

Investors: Peter Vozzo, ICR Healthcare, 443-213-0505 peter.vozzo@icrhealthcare.com

Exhibit 99.2

INOVIO Announces Pricing of $20.0 Million Public Offering

PLYMOUTH MEETING, PA – July 29, 2026 /PRNewswire/ – INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 21,052,632 shares of its common stock and accompanying warrants to purchase up to 42,105,264 shares of its common stock (or pre-funded warrants in lieu thereof) with an exercise price of $1.10 per share of common stock, at a combined public offering price of $0.95 per share of common stock and accompanying warrant to purchase two shares of common stock. INOVIO also granted the underwriter an option for a period of 30 days to purchase up to 3,157,894 additional shares of the Company’s common stock and/or warrants to purchase up to 6,315,788 additional shares of its common stock (or pre-funded warrants in lieu thereof) at the public offering price, less the underwriting discounts and commissions. All of the securities in the offering are being sold by INOVIO. The offering is expected to close on or about July 31, 2026, subject to the satisfaction of customary closing conditions.

The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by INOVIO, and excluding any exercise of the underwriter’s option to purchase additional securities and assuming no exercise of the accompanying warrants, are expected to be approximately $20.0 million.

Piper Sandler is acting as sole manager for the offering.

A shelf registration statement relating to the shares of common stock and accompanying warrants offered in the offering described above was filed with the Securities and Exchange Commission (“SEC”) on July 2, 2026 and declared effective by the SEC on July 10, 2026. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering were filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting: Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by e-mail at prospectus@psc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO’s technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools.

Forward-Looking Statements

This release contains or may imply “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding the public offering of INOVIO’s securities, including the timing of the closing of the offering, as well as the anticipated proceeds of the offering. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in INOVIO’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and in other filings that INOVIO makes with the SEC from time to time. There can be no assurance that any of the forward-looking information provided herein will be proven accurate. These forward-looking statements speak only as of the date hereof and INOVIO undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

Contacts

Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com

Investors: Peter Vozzo, ICR Healthcare, 443-213-0505 peter.vozzo@icrhealthcare.com

Filing Exhibits & Attachments

9 documents

Press Releases

• EX-99.1 EX-99.1 7.2 KB
• EX-99.2 EX-99.2 7.7 KB

Other Documents

• EX-1.1 EX-1.1 197.9 KB
• EX-4.1 EX-4.1 75.1 KB
• EX-4.2 EX-4.2 84.3 KB
• EX-5.1 EX-5.1 15.0 KB
• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB